Abstracts Archive - Page 1284 of 2425 - ACR Meeting Abstracts

Abstract Number: 1177 • 2017 ACR/ARHP Annual Meeting
Airway Findings in Patients with Relapsing Polychondritis
Marcela A. Ferrada¹, James D. Katz², Keith A. Sikora³, Allen Clint⁴, Jeff Kim⁴, Wendy Goodspeed⁴, Robert Colbert⁵, Marcus Chen⁶, Arlene Sirajuddin⁴ and Peter C. Grayson², ¹NIAMS, National Institues of Health, Bethesda, MD, ²National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ³Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵NIAMS/NIH, Bethesda, MD, ⁶NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare multiorgan disease. Involvement of the upper and lower airways is associated with significant morbidity and mortality. Isolated airway…
Abstract Number: 1178 • 2017 ACR/ARHP Annual Meeting
Sympathetic Joint Effusion in an Urban Hospital
Jessica L. Barlow¹ and Irene J. Tan^2,3, ¹Internal Medicine, Temple University Hospital, Philadelphia, PA, ²Temple University Hospital, Philadelphia, PA, ³Section of Rheumatology, Temple University Lewis Katz School of Medicine, Philadelphia, PA
Background/Purpose: Sympathetic joint effusion (SJE) or sympathetic synovial effusion (SSE) is a rheumatologic entity that has not been well defined in the medical literature. It…
Abstract Number: 1179 • 2017 ACR/ARHP Annual Meeting
A Multi-Organ Inflammatory Condition with Features of Idiopathic Multicentric Castleman’s Disease and IgG4-Related Disease: An Unrecognized Mimicker of IgG4-RD
Zachary S. Wallace¹, Yasuharu Sato², Kazuichi Okazaki³, Judith Ferry⁴, Hisanori Umehara⁵, Aliyah Sohani⁶, Mitsuhiro Kawano⁷, Nancy Harris⁶, Yoshiya Tanaka⁸, Cory A. Perugino⁹, Satoshi Kubo¹⁰, James Stone⁴, Robert Colvin⁴, Tsutomu Chiba¹¹, John H. Stone¹² and Yoh Zen¹³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Pathology, Okayama University Graduate School of Medicine, Okayama, Japan, ³Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka, Japan, ⁴Department of Pathology, Massachusetts General Hospital, Boston, MA, ⁵Kyoto University, Kyoto, Japan, ⁶Massachusetts General Hospital, Boston, MA, ⁷Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan, ⁹Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, ¹⁰The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹¹Department of Gastroenterology and Hepatology, Kyoto University, Kyoto, MA, ¹²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ¹³Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Some of clinical features of the plasma cell type of human herpesvirus-8-negative multicentric Castleman’s disease (idiopathic MCD or iMCD) are similar to those of…
Abstract Number: 1180 • 2017 ACR/ARHP Annual Meeting
Multicenter Study on the Rate of Renal Function Deterioration in IgG4-Related Tubulointerstitial Nephritis
Mitsuhiro Kawano¹, Ichiro Mizushima², Takahiro Matsunaga¹, Kazunori Yamada³, Satoshi Hara¹, Hiroshi Fujii¹, Takako Saeki⁴, Yoshinori Taniguchi⁵ and Hitoshi Nakashima⁶, ¹Division of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, ²Kanazawa University Hospital, Kanazawa, Japan, ³Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan, ⁴Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁵Department of Endocrinology, Metabolism, Nephrology and Rheumatology, Kochi Medical School, Kochi, Japan, ⁶Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Background/Purpose: Only a few reports have focused on the rate of renal function deterioration in IgG4-related tubulointerstitial nephritis (IgG4-TIN). Some cases show acute or progressive…
Abstract Number: 1181 • 2017 ACR/ARHP Annual Meeting
Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease
Jeong Seok Lee¹, Eun Young Lee², Jin Kyun Park³, Eun Bong Lee² and Yeong Wook Song⁴, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ⁴Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Measuring severity of interstitial lung disease (ILD) usually depends on the extent or pattern of imaging findings on computed tomography (CT) and the parameters…
Abstract Number: 1182 • 2017 ACR/ARHP Annual Meeting
Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events
Petra Budde¹, Jennifer Marte², Hans-Dieter Zucht¹, Saurabh Bhandari¹, Manuel Tuschen¹, Peter Schulz-Knappe¹, James Gulley², Christopher Heery³, Ravi Madan² and Jeffrey Schlom², ¹Protagen AG, Dortmund, Germany, ²National Cancer Institute, National Institutes of Health, Bethesda, MD, ³Bavarian Nordic, Inc., Morrisville, NC
Background/Purpose: Autoantibodies (AAB) targeting self-antigens can be found in two clinically and immunologically opposing diseases, autoimmune diseases and cancer. While in autoimmune diseases, the immune…
Abstract Number: 1183 • 2017 ACR/ARHP Annual Meeting
Bone Sarcoidosis: A Multicenter Study
Camille Glanowski¹, Raphaele Mestiri², Lisa Bialé³, Thierry Carmoi⁴, Gaëlle Leroux⁵, David Saadoun⁶, Catherine Chapelon-Abric⁷ and Patrice Cacoub⁸, ¹Internal Medicine, Hôpital d'instruction des armées de Bégin, Bégin, France, ²Hôpital d'instruction des armées du Val-de-Grâce, Paris, France, ³Hôpital d'instruction des armées de Bégin, Bégin, France, ⁴Service de Médecine Interne, Hôpital d'instruction des armées du Val-de-Grâce, Paris, France, ⁵Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁶Sorbonne Universités, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), F-75005, Paris, France; INSERM, UMR_S 959, F-75013, Paris, France; CNRS, FRE3632, F-75005, Paris, France; AP-HP, Groupe Hospitalier, Paris, France, ⁷AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ⁸Department of Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Background/Purpose: Studies on bone involvement of sarcoidosis (BS) are scarse. To analyze in depth main features, treatments and follow up of patients presenting a BS.…
Abstract Number: 1184 • 2017 ACR/ARHP Annual Meeting
Response to Methotrexate and Glucocorticoid Injection in New Onset Arthritis after Checkpoint Inhibitor Therapy
Lisa Christ¹, Jan Leipe¹, Ilana Goldscheider², Markus Heppt², Carola Berking², Frank Berger³, Claudia Dechant¹, Alla Skapenko¹ and Hendrik Schulze-Koops¹, ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ²Department of Dermatology and Allergology, University of Munich, Munich, Germany, ³Department of Radiology, University of Munich, Munich, Germany
Background/Purpose: The recent introduction of biologic agents targeting immunologic checkpoints (immunologic checkpoint inhibitors, ICI) established immunotherapy as a highly effective cancer therapy. ICI that trigger…
Abstract Number: 1185 • 2017 ACR/ARHP Annual Meeting
Acupotomy Therapy for Joint Pain Relief of Knee Osteoarthritis-Systematic Review and Meta-Analysis
Jia Li¹, Puwei Yuan², Rongqiang Zhang¹, Bin Chen³, Bo Dong¹, Wulin Kang¹, Xiaoliang Zhang³, Stephanie Hyon⁴, Raveendhara R. Bannuru⁵, William F. Harvey⁴ and Chenchen Wang⁴, ¹Shaanxi University of Chinese Medicine, Xianyang, China, ²Traditional Chinese Medicine College, Shaanxi University of Chinese Medicine, Xianyang, China, ³Integrative TCM and Western Medicine College, Shaanxi University of Chinese Medicine, Xianyang, China, ⁴Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, ⁵Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA
Background/Purpose: Knee osteoarthritis (KOA) is a major public health problem and a leading cause of long-term pain and disability. Few effective medical treatments for the…
Abstract Number: 1186 • 2017 ACR/ARHP Annual Meeting
A Simple, Self-Assembled Hydrogel Depot for Localized Treatment of Post-Traumatic Osteoarthritis
Jing Yan¹, Nitin Joshi², Xueyin He², Sachin Bhagchandani², Kai Slaughter², Nicholas Sherman¹, Joerg Ermann¹ and Jeffrey Karp², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Joint injuries, including sports- or combat-related ligamentous tears and fractures, can lead to post-traumatic osteoarthritis (PTOA), a chronic condition that causes pain, disability and…
Abstract Number: 1187 • 2017 ACR/ARHP Annual Meeting
Chondroitin Sulfate/Glucosamine Hydrochloride Induce a Reduction in Adrenergic Serum Markers in Osteoarthritis Patients Similar to That Produced By Celecoxib
Marta Herrero¹, Pedro Zapater^2,3, Helena Martinez¹, Rubén Francés^3,4, Josep Vergés⁵ and Jose F Horga², ¹Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ²Pharmacology Department, Miguel Hernández University, Alicante, Spain, ³CIBERehd. Carlos III Institute, Madrid, Spain, ⁴Medicine Department, Miguel Hernández University, Alicantes, Spain, ⁵Osteoarthritis Foundation International, Barcelona, Spain
Background/Purpose: Inflammation in osteoarthritis (OA) has been characterized by infiltration of immune cells and secretion of cytokines into synovial tissues. Noradrenaline levels, sympathetic nerve fiber…
Abstract Number: 1188 • 2017 ACR/ARHP Annual Meeting
Initial Estimates of Efficacy of Intra-Articular 2.5% Polyacrylamide Hydrogel for the Treatment of Knee Osteoarthritis: An Observational Proof-of-Concept Study
Marius Henriksen^1,2, Anders Overgaard¹ and Henning Bliddal³, ¹The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark, ²Department of physical therapy, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark, ³The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark
Background/Purpose: There is a draught of available effective treatments of knee osteoarthritis (OA) and tests of new therapies are needed. Polyacrylamide hydrogel (PAAG) is a…
Abstract Number: 1189 • 2017 ACR/ARHP Annual Meeting
Favorable Human Safety, Pharmacokinetics and Pharmacodynamics of the Adamts-5 Inhibitor GLPG1972, a Potential New Treatment in Osteoarthritis
Ellen van der Aar¹, Sonia Dupont², Liesbeth Fagard¹, Marina De Smet¹, David Amantini², Staffan Larsson³, André Struglics³, L. Stefan Lohmander⁴, Frédéric Vanhoutte¹ and Julie Desrivot², ¹Galapagos NV, Mechelen, Belgium, ²Galapagos SASU, Romainville, France, ³Clinical Sciences, Lund University, Lund, Sweden, ⁴Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose: Increased aggrecanase activity is a well-known trigger factor for osteoarthritis (OA), initiating loss of cartilage aggrecan that precedes more severe cartilage degradation. A disintegrin…
Abstract Number: 1190 • 2017 ACR/ARHP Annual Meeting
Orosomucoid 2 Serves As Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine Hydrochloride
Valentina Calamia¹, M Camacho¹, Ignacio Rego-Pérez¹, L González¹, P Fernández-Puente¹, F Picchi¹, Marta Herrero², Helena Martinez², C Ruiz-Romero¹ and Francisco J Blanco^3,4, ¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, Spain, ²Clinical R&D Area, Bioiberica, SAU, Barcelona, Spain, ³RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain, ⁴Rheumatology Division, ProteoRed/ISCIII, Proteomics Group, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Orosomucoid 2 Serves as Predictor of Therapeutic Response in Osteoarthritis Patients Treated with Chondroitin Sulfate/Glucosamine HydrochlorideV. Calamia, M. Camacho, I. Rego-PŽrez, L. Gonz‡lez, P. Fern‡ndez-Puente,…
Abstract Number: 1191 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Cntx-4975 in Subjects with Moderate to Severe Osteoarthritis Knee Pain: 24-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Randall Stevens¹, Dena Petersen², John Ervin³, Jennifer Nezzer⁴, Yeni Nieves⁴, James Campbell¹, Kimberly Guedes¹, Robin Burges¹ and Peter Hanson¹, ¹Centrexion Therapeutics, Boston, MA, ²Noble Clinical Research, Tucson, AZ, ³Center for Pharmaceutical Research, Kansas City, MO, ⁴Premier Research, Durham, NC
Background/Purpose: CNTX-4975, a highly purified, synthetic trans-capsaicin, targets transient receptor potential vanilloid 1, producing analgesia via reversible desensitization of end terminals of primary afferent pain…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].